Insight Molecular Diagnostics Inc (IMDX)

$6.85 -0.38 (-5.26%)
Market Cap 203.80M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 76,800
Avg Vol 60,090
Day's Range N/A - N/A
Shares Out 28.66M
Stochastic %K 33%
Beta 1.11
Analysts Sell
Price Target $7.00

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
JohnTrack
JohnTrack Jan. 13 at 9:56 PM
$IMDX no rush, eyes on this!!!
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 7:51 PM
$IMDX new blurb just went live... https://www.rapidticker.com/news/imdx-imdx-supports-ast-and-ashi-9d2292
0 · Reply
JohnPDaly
JohnPDaly Jan. 13 at 2:11 PM
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-13-2026-140452877
0 · Reply
JohnPDaly
JohnPDaly Jan. 12 at 2:48 PM
$LCTX $IMDX bought more.
0 · Reply
Bogwood
Bogwood Jan. 9 at 6:51 AM
$IMDX Have any of you guys reached out to IR about EU competitors like Devyser or Eurobio/GenDX? They make kitted NGS assays, and Dev has a commercial partner in Thermo Fisher and going through an albeit later FDA trial for ddcf-DNA. If not I will ask for the group
1 · Reply
JohnPDaly
JohnPDaly Jan. 6 at 1:20 PM
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-06-2026-130348318
1 · Reply
RUNNINWILD
RUNNINWILD Jan. 5 at 3:33 PM
$IMDX they days of cheap shares I’m afraid is going to be coming to an end
1 · Reply
JohnTrack
JohnTrack Jan. 5 at 2:33 PM
$IMDX Prepares for U.S. Commercial Launch of GraftAssureDx https://www.rapidticker.com/news/imdx-imdx-prepares-for-us-commercial-df3b8b
0 · Reply
JohnPDaly
JohnPDaly Jan. 5 at 12:07 PM
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-05-2026-120057265
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 4:38 PM
$IMDX RSI: 69.10, MACD: 0.3052 Vol: 0.78, MA20: 5.65, MA50: 6.10 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on IMDX
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 13, 2026, 9:00 AM EST - 1 day ago

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Jan 7, 2026, 4:05 PM EST - 7 days ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Jan 6, 2026, 8:00 AM EST - 8 days ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Jan 5, 2026, 7:00 AM EST - 9 days ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:31 AM EST - 2 months ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 10, 2025, 4:05 PM EST - 2 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Nov 3, 2025, 4:05 PM EST - 2 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 13, 2025, 4:05 PM EDT - 3 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Oct 6, 2025, 7:15 AM EDT - 3 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 24, 2025, 7:05 AM EDT - 4 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:15 AM EDT - 4 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Sep 8, 2025, 7:00 AM EDT - 4 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 26, 2025, 4:05 PM EDT - 5 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 11, 2025, 4:05 PM EDT - 5 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Aug 4, 2025, 4:05 PM EDT - 5 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 30, 2025, 4:05 PM EDT - 6 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jul 28, 2025, 4:05 PM EDT - 6 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 7 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 7 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 8 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 8 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 8 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 9 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 9 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 9 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 10 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 10 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 1 year ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

JohnTrack
JohnTrack Jan. 13 at 9:56 PM
$IMDX no rush, eyes on this!!!
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 7:51 PM
$IMDX new blurb just went live... https://www.rapidticker.com/news/imdx-imdx-supports-ast-and-ashi-9d2292
0 · Reply
JohnPDaly
JohnPDaly Jan. 13 at 2:11 PM
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-13-2026-140452877
0 · Reply
JohnPDaly
JohnPDaly Jan. 12 at 2:48 PM
$LCTX $IMDX bought more.
0 · Reply
Bogwood
Bogwood Jan. 9 at 6:51 AM
$IMDX Have any of you guys reached out to IR about EU competitors like Devyser or Eurobio/GenDX? They make kitted NGS assays, and Dev has a commercial partner in Thermo Fisher and going through an albeit later FDA trial for ddcf-DNA. If not I will ask for the group
1 · Reply
JohnPDaly
JohnPDaly Jan. 6 at 1:20 PM
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-06-2026-130348318
1 · Reply
RUNNINWILD
RUNNINWILD Jan. 5 at 3:33 PM
$IMDX they days of cheap shares I’m afraid is going to be coming to an end
1 · Reply
JohnTrack
JohnTrack Jan. 5 at 2:33 PM
$IMDX Prepares for U.S. Commercial Launch of GraftAssureDx https://www.rapidticker.com/news/imdx-imdx-prepares-for-us-commercial-df3b8b
0 · Reply
JohnPDaly
JohnPDaly Jan. 5 at 12:07 PM
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-05-2026-120057265
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 4:38 PM
$IMDX RSI: 69.10, MACD: 0.3052 Vol: 0.78, MA20: 5.65, MA50: 6.10 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RUNNINWILD
RUNNINWILD Dec. 31 at 12:47 AM
$IMDX i see you.
1 · Reply
SynthesisSage
SynthesisSage Dec. 26 at 2:10 PM
$IMDX Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Cash efficiency must trend upward while maintaining strategic flexibility. Demonstrated durability would lengthen investor time horizons. The forward path ultimately depends on disciplined delivery.
0 · Reply
JohnPDaly
JohnPDaly Dec. 24 at 7:48 PM
$IMDX Thanks!
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 2:17 PM
$IMDX Share Price: $5.41 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.68 – $3.28 Potential Upside: 65% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Bogwood
Bogwood Dec. 11 at 6:03 PM
$IMDX Even with all of this year's press releases and events, most still don't see what's going to happen to transplant diagnostics next year and see the situation as not yet "derisked". Do not be deterred by recent price movement fellow holders! The path to $100M top line will light like a tinder box. 80% of the top transplant centers already perform HLA in-house. $NTRA and $CDNA can kiss their biz model goodbye 💋
2 · Reply
RUNNINWILD
RUNNINWILD Dec. 4 at 2:09 AM
$IMDX https://diagnostics.roche.com/global/en/lab-leaders/article/molecular-laboratory-trends.html#:~:text=However%2C%20in%20the%20future%2C%20molecular,drug%20metabolism%20and%20treatment%20response.
0 · Reply
SERaiser
SERaiser Dec. 2 at 3:08 AM
$IMDX Did they submit their FDA Assay?
1 · Reply
RUNNINWILD
RUNNINWILD Dec. 1 at 11:58 PM
$IMDX asked AI why the stock is going down
1 · Reply
TradeWoFear
TradeWoFear Dec. 1 at 9:20 AM
$IMDX watchout ....forecasted by CNN!!!!!!!!!1
1 · Reply
RUNNINWILD
RUNNINWILD Nov. 21 at 4:02 PM
$IMDX goodluck trying to get any orders filled
0 · Reply
Bogwood
Bogwood Nov. 20 at 5:38 PM
$IMDX Ekke continues to file patents related to colorectal cancer. Given today's news about $EXAS, friendly reminder that they operate a central lab to process samples...
0 · Reply
Bogwood
Bogwood Nov. 20 at 4:04 AM
$IMDX Clinical trial updated today; only added a couple more sites. In-line with expectations that data will be complete by year-end. I think we prefer to see more sites recruiting as that implies each lab staff members are trained up in the workflow, akin to the 'land and expand' strategy
0 · Reply